Mesoblast (MESO) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Mesoblast Limited has issued 2 million unquoted warrants as part of a US$50 million convertible note facility, which the company can utilize following FDA approval. Each warrant can convert into one ordinary share or into American Depositary Receipts at a specified exchange rate. This strategic move aims to bolster Mesoblast’s financial flexibility and potential market positioning.
For further insights into MESO stock, check out TipRanks’ Stock Analysis page.